A Study of Imvotamab in Severe Systemic Lupus Erythematosus

Study Purpose

The purpose of this study is to determine the safety and tolerability of imvotamab in patients with severe systemic lupus erythematosus who have failed prior therapies. Participants will be given imvotamab through a vein (i.e., intravenously).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria


Inclusion Criteria:

  • - Age ≥ 18 years at the time of signing ICF.
  • - Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (ACR) Classification Criteria at least 16 weeks or more prior to screening.
  • - Highly active SLE disease, as demonstrated by a total systemic lupus erythematosus disease activity index (SLEDAI-2K) total score of ≥ 10 at screening.
  • - Active SLE disease despite treatment with at least 1 immunosuppressive or biologic standard-of-care agent (e.g., methotrexate, azathioprine, mycophenolate mofetil, belimumab, anifrolumab) determined at the discretion of the investigator after at least 3 months of treatment.
  • - It must be planned that the background standard-of-care treatment remains at a stable dose throughout the Screening Period and up to Week 8.

Exclusion Criteria:

  • - Pregnant or breastfeeding or intending to become pregnant during the study or within 3 months after the final dose of imvotamab.
  • - Any lupus-associated neuropsychiatric disease.
  • - Active lupus nephritis with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2, calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation, classified as World Health Organization (WHO) Class IV.
  • - Prednisone-equivalent > 30 mg/day, including immediate and extended-release oral formulations.
  • - Drug-induced lupus.
  • - Participants with a history of catastrophic or severe anti-phospholipid syndrome within 12 months prior to screening.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

IGM Biosciences, Inc.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Rebecca Kunder
Principal Investigator Affiliation IGM Biosciences
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Recruiting
Countries United States

The disease, disorder, syndrome, illness, or injury that is being studied.

Systemic Lupus Erythematosus, Lupus Erythematosus
Additional Details

This is a Phase 1b, randomized, placebo-controlled, multicenter study to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of imvotamab in adult participants with systemic lupus erythematosus (SLE). Approximately 18 participants will be assigned to different sequentially dose escalation cohorts.

Arms & Interventions


Experimental: Imvotamab (Dose Escalation)

Imvotamab administered intravenously


Drug: - Imvotamab

Administered intravenously

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

East Bay Rheumatology, San Leandro, California




East Bay Rheumatology

San Leandro, California, 94578

Site Contact

Clinical Trials

[email protected]

(877) 544-6728

Omega Research, DeBary, DeBary, Florida




Omega Research, DeBary

DeBary, Florida, 32713

Site Contact

Clinical Trials

[email protected]

(877) 544-6728

Care and Cure Clinic, Houston, Texas




Care and Cure Clinic

Houston, Texas, 77090

Site Contact

Clinical Trials

[email protected]

(877) 544-6728